Overall I think the strategy to acquire a complimentary and synergistic technology is a smart one for RSH, providing a complete monitoring solution for asthma patients and adding further diversification to the portfolio.
What is puzzling me is how does ADR conduct a capital raise that is larger than the company's current market cap ?
So investors are giving the Board more money than what the market says the company is worth today ?
Can anybody explain that for me?
Ann: Proposed issue of Securities - RSH, page-133
-
- There are more pages in this discussion • 95 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RSH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $33.24M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 110000 | 2.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.0¢ | 121551 | 1 |
View Market Depth
| Last trade - 16.12pm 25/07/2024 (20 minute delay) ? |
| RSH (ASX) Chart |
Day chart unavailable